originally made in 1995 at Myogenics.
also FDA-approved for use in the treatment of multiple myeloma & mantle
§Bortezomib is a
dipeptide Boronic acid derivative and proteasome inhibitor used to treat
multiple myeloma and mantle cell lymphoma.
§Bortezomib has a
role as an antineoplastic
proteasome inhibitor, a protease
• an antiprotozoal
are in cells. They help to break down proteins that the cell doesn't need.
Bortezomib b blocks the
proteasomes so the proteins build up inside the cell. The cell then dies.
inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus
and cytosol of all eukaryotic cells.
tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.